ResMed Inc. (RMD) Stock Analysis
Temp Headwind edge
Healthcare · Medical Instruments & Supplies
Wait for pullback to $188.39. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $192.22. Engine's entry $188.39 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-MA, MA slope -4.5%/30d (confirmed downtrend).
ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory conditions through its Sleep and Breathing Health segment, plus Residential Care Software for HME/home health providers. With 10,600+ employees selling in 140+... Read more
Wait for pullback to $188.39. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $192.22. Engine's entry $188.39 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-MA, MA slope -4.5%/30d (confirmed downtrend). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Score 6.0/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — ResMed Inc.
Latest news
- NEWS ResMed Earnings: What To Look For From RMD - Yahoo Finance — Yahoo Finance neutral
- NEWS Wall Street's Insights Into Key Metrics Ahead of ResMed (RMD) Q3 Earnings - Yahoo Finance — Yahoo Finance positive
- NEWS ResMed (NYSE:RMD) Sets New 1-Year Low - What's Next? - MarketBeat — MarketBeat negative
- NEWS ResMed Earnings: What To Look For From RMD - StockStory — StockStory neutral
- NEWS 3 reasons not to sleep on ResMed stock - MSN — MSN positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-04-30Item 5.02MEDIUMCFO Brett Sandercock retiring effective May 4, 2026, transitioning to Special Advisor through December 2027. Aaron Bloomer, formerly CFO of Exact Sciences, appointed CFO effective May 4, 2026. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $188.39. Weak momentum; also below 200-day MA (death cross), recent C-suite change — blocks BUY_NOW at $192.22. Engine's entry $188.39 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Negative momentum; Below 200-MA, MA slope -4.5%/30d (confirmed downtrend). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. Target $243.54 (+26.7%), stop $176.20 (−9.1%), Setup A.R:R 5.0:1. Score 6.0/10, moderate confidence.
Take-profit target: $243.54 (+30.8% upside). Target $243.54 (+26.7%), stop $176.20 (−9.1%), Setup A.R:R 5.0:1. Stop-loss: $176.20.
Negative momentum; Below 200-MA, MA slope -4.5%/30d (confirmed downtrend).
ResMed Inc. trades at a P/E of 18.8 (forward 16.0). TrendMatrix value score: 7.0/10. Verdict: Buy (Wait for Entry).
25 analysts cover RMD with a consensus score of 3.6/5. Average price target: $271.
What does ResMed Inc. do?ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory...
ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory conditions through its Sleep and Breathing Health segment, plus Residential Care Software for HME/home health providers. With 10,600+ employees selling in 140+ countries, ~64% of net revenues come from the U.S.